LB008/#180 KGOG3056/Nirvana-R Trial: Efficacy of Maintenance Niraparib Rechallenge Plus BEV According to Minimal Residual Disease (MRD) Assessment in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor